Regulation & Compliance

The return of a critical antibiotic after 14 years via a new, ultra-fast FDA pathway signals a major shift in U.S. industrial and health policy.

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.

Sarepta Therapeutics is trading higher interest costs for a longer financial runway. We decode the biotech's complex debt deal and what it signals.

As AI-driven fakes flood the world, a new asset class is born: authenticity. Discover how GME and Reality Defender are monetizing trust for government.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

With a massive $550M capital infusion, Immunovant is poised to accelerate its novel Graves' Disease therapy, IMVT-1402, toward commercial launch.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

A new partnership aims to bypass slow, costly banking rails, using stablecoins to unlock faster, cheaper global transactions for businesses. Is this the future?

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

How empowering 4,500 employees with $100 each transformed corporate giving, creating a wave of support for 2,100 charities nationwide.

On Human Rights Day, Ottawa touts global leadership, but a chasm grows between its international promises and the stagnant progress on justice at home.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

A minor share sale by a US giant in a UK tech firm reveals the subtle art of institutional investing and the power of regulatory transparency.

A new partnership seeks to unify viewership, channel, and ad data across all 210 US markets, promising unprecedented precision for local advertisers.